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S300 Poster Session Ifrom 2000-2011. Patients included in the analysis all achieved CR1
or PR1 by CIBMTR definition prior to transplant. Patients who re-
ceived tandem transplants, allogeneic transplants, or whowere trans-
planted on clinical protocol were excluded. Disease status prior to
transplant and disease status 100 days after transplant was recorded
for both patients younger than 65 and 65 years of age and older.
Data from transplants of 117 patients were analyzed. 32 patients
(27%) were age 65 and older, and 85 patients (73%) were younger
than age 65. Prior to transplant, 20/32 patients (63%) age 65 and
above were in CR or VGPR compared to 23/85 (27%) of patients
younger than age 65. At 100-day restaging after transplant, 25/32 pa-
tients (78%) age 65 and above achieved a CR or VGPR compared to
44/85 patients (52%) younger than 65. There was one transplant-re-
lated death in each age group corresponding to a transplant-related
mortality of 3% and 1% in the older and younger age groups, respec-
tively. Two patients who were both younger than age 65 had evi-
dence of progressive disease at 100-day restaging.
Based on our single-institution analysis, multiple myeloma pa-
tients age 65 and above have experienced similar outcomes compared
to younger patients with respect to transplant-related mortality and
disease status 100-days after transplant. Specifically both age groups
experienced a consolidative benefit to high-dose therapy followed by
autologous SCT. Prospective studies evaluating the impact of age on
transplant outcome should be performed for further investigation.
Table 1. Characteristics of Myeloma Patients Transplanted at
Temple from 2000-2011Number of PatientsTable 1.
Patient # AGE
Induction pre
1st Transplant
1 46 VAD X4 then
Thalidomide
for 1 year
C
2 66 VAD X4 C
3 56 Thal/Dex then
Bro/Dex then MP
C
4 67 Lenalidomide/Dex  4 G
X indicates number of cycles; RVD, lenalidomide
Doxorubicin, Cytoxan, Etoposide; Bro, Brotezom117
Median Age 58
Range of Ages 40-77
Age 65 and greater 32
Younger than Age 65 85
Number of Males 70
Number of Females 47
IgG Subtype 62
IgA Subtype 24
Free Kappa Light Chain 16
Free Lambda Light Chain 11
Other (IgD, Oligoclonal, Non-secretory) 4
Median Time from diagnosis to BMT 11.5 months
Median CD34 dose 5.56E + 06 cell dose/kg259
SUCCESSFUL STEM CELL MOBILIZATION AND ENGRAFTMENT IN
HEAVILY PRETREATED MULTIPLE MYELOMA PATIENTS WITH PRIOR
HIGH DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTA-
TION
Khaled, Y., Solh, M., Lamontagne, D., Batista, A., Sullivan, J., Chan-
Fong, S., Fondaw, M., Reddy, V. Florida Cancer Institute, Orlando, FL
Salvage second autologous transplantation for patients with re-
lapsed multiple myeloma (MM) after prior autologous transplanta-
tion has shown to be beneficial in particular if the first remission isMobilization
Regimen
First
Transplant T
ytoxan/G-CSF Single
ytoxan/G-CSF Planned
Tandem
ytoxan/G-CSF Single
-CSF Single
, Bortezomib, Dex.; Thal, Th
ib.longer than 12-18 months. In addition second salvage autologous
transplant may be used in the contest of progressive refractory mye-
loma for temporarily disease control or for hematopoietic reconsti-
tution after prior extensive therapy. Customarily, patients with
multiple myeloma who received prior alkylating agents or autolo-
gous transplantation with high dose Melphalan are considered non
transplant candidate because of the deleterious effects on stem cell
collection. Plerixafor is a chemokine receptor -4- antagonist which
is approved by FDA for use in combination with G-CSF for mobili-
zation of CD34+ stem cells in patients with NHL and multiple my-
eloma. We have explored the feasibility of Plerixafor and G-CSF in
stem cell collection for second salvage autologous transplantation in
4 consecutive patients with multiple myeloma who underwent prior
extensive therapy including prior autologous transplantation with
Melphalan-200. Patient characteristics, chemotherapy used and in-
terval between first and second salvage transplant are shown in
Table 1. All Patients received GCSF at dose of 10 mcg/KG for 4
days in AM, Plerixafor on the evening of the 4th night and subsequent
nights prior to apheresis at a dose of 0.24 mg/kg. The number of
apheresis procedures were 2 in two patients and 3 in two patients.
The number of CD34 + cells collected were 4.25, 3.06, 3.63, 3.78
million cells/Kg. All the patients engrafted successfully after the sec-
ond transplant. Neutrophils engraftement were at day 10, 12, 12 and
11 while platelet engraftment were at day 10, 15, 32 and 19 respec-
tivlely for the four patients.
Our Data shows the feasibility of stem cell collection in heavily
pretreated MM patients including high dose Melphalan and autolo-
gous stem cell transplantation. Prospective studies are needed to
confirm such feasibility. Such approach may have future clinical ap-
plication in eliminating minimal residual disease after the first autol-
ogous transplant when used in MM patients with planned upfront
tandem autologous transplant.
PEDIATRIC DISORDERS260
A TREOSULPHAN BASED REDUCED TOXICITY CONDITIONING PROTO-
COL FOR THALASSAEMIA MAJOR
Raj, R., Munirathnam, D., Khandelwal, V., Sri, K., Bhushan, V.,
Kumar, M., Lakshmanan, V. Apollo Speciality Hospital, Chennai, Tamil-
nadu, India
We present data comparing two conditioning protocols for beta
thalassaemia major in patients treated in our unit from 2005 to
2011.Twenty children aged between 2 and 9 years were treated using
oral busulphan 16 mg/kg/day with cyclophosphamide 200 mg/kg/
day were assigned to group one. Twenty children aged between 1
and 14 years were treated using thiotepa 8 mg/kg, treosulphan 42
gm/m2 and fludarabine 160 mg/m2 were assigned to group two.
Datawas analysed retrospectively forLucarelli class,mucositis, blood
product requirement, need for parenteral nutrition, engraftment and
transplant relatedmortality. Group one had 4 class I, 10 class II and 6
class III patients between age groups 1 to 14 years. Mucositis was
grade two and above in 11 children and they needed partial parenteralype
Maintenance/Relapse
treatment Re-Induction
Interval between
transplants (Years)
Thalidomid then
Lenalidomide
maintenance
RVD  3 8.57
Dex/Thal followed
by Bro/Doxil
MPV-Rituximab 4.77
Dex/Thal then
RVD3 then
VD-PACE
MPV-Rituximab 2 4.43
Lenalidomide
maintennace for
15 months
RVD  4,
VD-PACE 2
1.75
alidomide; MPV, Melphalan, Prednisone , Bortezomib; PACE, Cisplatin,
